

APPENDIX C -
SUMMARY OF RESULTS TO DATE:

| Allergen | Plant Source | Particle | Result | Reference |
|---|---------------------|---|--|---|
| rPhl p 5b | Timothy Grass | cyanogen bromide-activated spherical Sepharose (also referred to as “beaded agarose”) having a mean diameter of 2.1 µm | Immunization of BALB/c mice yielded: <ul style="list-style-type: none"> - a pronounced allergen-specific IgG response (IgG₁, IgG₂, IgG₃) comparable to that of an Alum-based equivalent (Example 1); - a stronger cytokine response (IFN-γ, IL-5, IL-4) than that of an Alum-based equivalent (Example 2); - reduced inflammatory reaction and granulomatous response as compared to an Alum-based equivalent (Example 3); and - sera capable of inhibiting the binding between allergen and allergic patient IgE, having a blocking capacity compared to that of an Alum-based equivalent (Example 5). | Applicants’ specification (US 2005/0095298); See also Gronlund et al., Immunology (2002), vol. 107-523-529 (of record) |
| rFel d 1 | Cat Dander | cyanogen bromide-activated spherical Sepharose having a mean diameter of 2.1 µm | Immunization of BALB/c mice serving as a mouse model for cat allergic asthma yielded: <ul style="list-style-type: none"> - pronounced allergen-specific IgG and IgG₂ responses that correlate to the presence of blocking antibodies; and - reduced infiltration of eosinophils in the BAL fluid and reduced AHR after methacholine challenge, both of which correlate to clinical efficacy in the context of treating allergen-induced airway symptoms. | Neimart-Andersson et al., Allergy (2008), vol. 63: 518-526 (of record) |
| Hybrid “G-antigen” (Phl p 1, Phl p 2, Phl p 5, and Phl p 6) | Timothy Grass | cross-linked agarose beads, pre-activated with N-hydroxysuccinimide and having an expected diameter on the order of 30 µm | Immunization of BALB/c mice yielded: <ul style="list-style-type: none"> - a pronounced allergen-specific IgG₁ response (Figure 1); and - a pronounced allergen-specific T-cell response (Figure 2) | Appendix A (new data) |

APPENDIX C -
SUMMARY OF RESULTS TO DATE:

| Allergen | Plant Source | Particle | Result | Reference |
|---|---------------------|---|--|---|
| rBet v 1 derivatives (i.e. Bet v 1F1 and Bet v 1F2) | Birch Pollen | cross-linked agarose beads, pre-activated with N-hydroxysuccinimide and having an expected diameter on the order of 30 µm | Immunization of BALB/c mice yielded: <ul style="list-style-type: none"> - a pronounced allergen-specific IgG₁ response comparable to that of an Alum-based equivalent (compare Figure 1 of Appendix B with Figure 4B of Pauli et al., JACL (2008), vol. 122(5): 957); and - reduced inflammatory reaction and granulomatous response as compared to an Alum-based equivalent. | Appendix B (new data) |
| rBet v 1 | Birch Pollen | aluminum hydroxide | Immunization of patients with birch pollen allergy over a 2 year period yielded: <ul style="list-style-type: none"> - an intense induction of allergen-specific IgG antibodies; - a reduction in clinical symptoms of birch rhinoconjunctivitis and birch-pollen induced skin reactivity; and - no serious or systemic adverse effects | Pauli et al., JACL (2008), vol. 122(5): 951-960 (of record) |